Agreements

Date: 2017-03-10

Type of information: Research agreement

Compound: novel T cell therapies

Company: Crispr Therapeutics (Switzerland - UK) Neon Therapeutics (USA - MA)

Therapeutic area: Cancer - Oncology

Type agreement: R&D - research

Action mechanism:  gene editing technology/cell therapy. “CRISPR” refers to Clustered Regularly Interspaced Short Palindromic Repeats that occur in the genome of certain bacteria, from which the system was discovered. Cas9 is a CRISPR-associated endonuclease known to act as the “molecular scissors” that cut and edit, or correct, disease-associated DNA in a cell. A guide RNA directs the Cas9 molecular scissors to the exact site of the disease-associated mutation. Once the molecular scissors make a cut in the DNA, additional cellular mechanisms and exogenously added DNA will use the cell’s own machinery and other elements to specifically ‘repair’ the DNA. This technology may offer the ability to directly modify or correct the underlying disease-associated changes in the human genome for the potential treatment of a large number of both rare and common diseases.

Disease:

Details:

•  On July 10, 2017, CRISPR Therapeutics and Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, announced a research collaboration to explore the combination of each company’s proprietary technologies to develop novel T cell therapies. The collaboration will explore gene-based technologies from CRISPR Therapeutics with Neon Therapeutics'expertise in neoantigen science and T cell biology.

Financial terms:

Latest news:

Is general: Yes